Research
Hormonal
Obesity in postmenopausal women increases breast cancer risk and recurrence through hormonal mechanisms, specifically elevated estrone, estradiol, insulin, and IGF-1 levels, and reduced sex hormone-binding globulin (SHBG).
For postmenopausal women, excess body fat is not just a storage issue but a hormonal one. Fat tissue produces estrogen and affects insulin/IGF-1 levels, which can fuel breast cancer growth. Reducing body fat may help normalize these hormone levels, potentially lowering the risk of cancer progression.
GoodSupportsHIGH confidence
Obesity is associated with higher concentrations of estrogens in postmenopausal women... obese postmenopausal women have higher blood concentrations of both estrone and estradiol and lower concentrations of sex hormone–binding globulin (SHBG)... Obesity... increases circulating concentrations of insulin and insulin-like growth factor-1 (IGF-1)...
Why this rating
Based on multiple prospective studies and cohort analyses linking hormone levels to breast cancer risk.
Source
Weight Loss in Breast Cancer Patient Management
Rowan T. Chlebowski · Journal of Clinical Oncology · 2002
DOI 10.1200/jco.20.4.1128
narrative_reviewCited 227×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity and post-diagnosis weight gain in breast cancer patients are associated with significantly increased risks of disease recurrence and mortality.Good
- Weight gain after breast cancer diagnosis, particularly following adjuvant chemotherapy, is a common occurrence that is associated with increased recurrence risk and reduced survival.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →